A comprehensive study by Boston Consulting Group, surveying over 10,600 people across 12 countries, reveals that women undergoing hormonal transitions are the industry’s most engaged demographic. These women adopt longevity interventions at rates 15 to 22 percentage points higher than their peers, yet their satisfaction levels stagnate at 50%. Despite a median monthly spend of $84—the highest among all groups surveyed—a third of these women indicate they would increase their investment if the market provided effective, specialized solutions.

The industry's primary oversight is timing. While companies typically target women only upon the onset of menopause, the data suggests that interest in long-term health spikes between ages 36 and 38, driven by early hormonal shifts and fertility concerns. Parul Bajaj, a managing director at BCG, notes that treating these mid-life changes as mere short-term symptoms rather than significant health milestones creates a critical blind spot. Furthermore, the healthcare system itself struggles to bridge this divide; only 63% of women consult doctors for hormone-related issues, and of those who do, nearly 30% report feeling that their concerns are not taken seriously by providers.

Addressing this mismatch requires a fundamental shift in how the longevity sector approaches research and provider training. As Mark Abraham, a global leader at BCG, highlights, the market is currently failing to convert high consumer intent into actual value. Companies that pivot to address these biological realities earlier in the aging process stand to capture a significant share of the $350 billion in dormant demand.